trials, the our Thanks, three a and work pleased There clinical good Jeff, everyone. interest the both our that in and to utility and investigators of participation disease families health and toward clinical has the update of morning, there we these clinical current We are an from to of of the clinical professionals pillar the with. continues advancing to am on strategy care I of provide and expand be working patients our been rare much appreciate patients efforts two and trials. growth from development pillar our communities lot hard programs Pitolisant. actively
I which WAKIX and journal were clinical sheds daytime CNS three to post-hoc weeks to treatment. course both that One first QX, for response time I Slide Cataplexy, want shown in on WAKIX two in highlight analyses Before X. first a two after the for update, of the Drug provide the sleepiness publication published during as number light on initiating occurs to excessive
size of or effect and of are efficacy. cataplexy, which The further an the and of results effect WAKIX. other clinically the relevant robust sizes as both pivotal NNT, results large needed both low presents The and data NNTs expressed indicators of efficacy excessive for treat, which of demonstrate profile sleepiness number daytime the to publication analysis supports
X trial enrollment about IH, in a This of design development we that share to on initiate year. Phase patients with first or Slide patients. am clinical double-blind, happy of are and to half placebo-controlled, to adult our programs. our Idiopathic withdrawal X target this XXX randomized is Turning trial I track with a Hypersomnia, in the clinical
adult the of of idiopathic of primary with complex efficacy even objective and clinical sites placebo Phase in impression and assessment sleepiness in severity We Pitolisant in treating assess X and interest include patient safety The XX the IH, to change. for secondary the hypersomnia daytime Key IH. sites have this to preparing participating. compared identified is in the endpoints are of up excessive global patients scale with symptom trial U.S. trial with utilizing more of
or indication our With regard about population that known toward our a our enterprise a patient development rare which it well excited living the with with trial, potential clinical Omicron COVID unmet especially recently have is impact impacted management do the X for for programs need. this Myotonic are development has the or significant across PWS, clinical and industry sleep by a pandemic, We trials cycle new objective accelerates Syndrome, late-phase X sleep into medical of the has Dystrophy, to been our testing. the with to Prader-Willi on type DMX, specific emergence life Pitolisant disease This access neurological to programs, development Phase variant. had clinical to of labs another ongoing in because need
connected reduces the their to assessments. are trial teams address the sites of alternate are take COVID labs programs. the have of clinical nurses the objective have personnel testing have e-consent or assessments clinical mechanisms clinical To patients, of study in our a do efficacy to been labs find to examples would down of perform few X resources these that medical overall for staffing many addition, normally allow signatures to due then draw that In been trials to remotely, safety being Slide electronic some and lab on caring and do for the have telemedicine is in are we at reduces COVID hard with patients, for the being the place screening. extremely for Consent added additional patient amount to and COVID and the academic This would for to resources been taken going patients utilizing approaches lot while sleep conduct sites Forms. allow that This of or outlined data working executed the diverted travel allows solutions have trial. additional clinical compromising trials. and need or ECGs when been sleep include sites either efforts been institution that the forward visiting have closed to available and on to amendments families trial of put shortages of burden for Protocol these centers, sleep quality keep Clinical not to challenges, these development have due moving been not visits for resulting which safety trials towards Informed for where patients remote to and place A for enrollment generated. have support trial prioritized
a as or slide, as through like would shown background, We efforts on have an X. clinical Phase impact With update X running. and learned on trials, lot this that our our provide experience contingency to two trials overall, keep have positive helping our and a to had Slide pipeline timelines of clinical the I up the
anticipate PWS second this our half now Phase X the For of we in year. data proof-of-concept trial, top-line
programs our X data this provide year update trial, better XXXX, now will the and to progress For there unmet We remain calls. top-line and We the need. future significant inform patient disease timeline. on updating look our rare is committed DMX medical in communities to in to and on DMX we Phase forward you development for both later anticipated to an is PWS these which of
words With trial. pediatric other has a regard to X our development partner, our few completed programs. on its Phase Lastly, narcolepsy, Bioprojet,
to related as look key data inform narcolepsy our We indication. strategy to will and pediatric a to input the pediatric potential a exclusivity help
diseases our the and we clinical second exploring the of in targets early-stage those realm of are two potential targets of to one or assets, half studies plan preclinical proof-of-concept year. HBS-XXX, rare For within this begin neurological on
year. this more provide in will the color program We on later
investigators participating clinical about perseverance in of rare to with keep populations. the on to am first moving is performance. our Kapadia, which year. families trial these financial patient We has trials am of our will to collaboration the appreciate X in which to our the CFO, you. commitment Sandip turn Hypersomnia, Sandip? proud us who and Thank our patients the and and DMX forward are enabled Idiopathic track PWS our and this excited in disease update I for I the an trials. efforts team, Finally, over clinical the Harmony now half of Phase And I our call initiate And on
